ScholarLens Back to search
2010•Journal watchRequires access

Combination Therapy for Early Unfavorable Hodgkin Lymphoma

Michael E. Williams

Open publisher page 0 citations

Abstract

Combined modality chemotherapy plus involved field radiotherapy (IFRT) provides high cure rates in patients with stage I–II Hodgkin lymphoma (HL). However, each modality carries excess risks for acute and delayed toxicities and for relapse among patients with unfavorable clinical features. To compare outcomes associated with various chemotherapy regimens and IFRT doses, investigators in the German Hodgkin Study Group conducted a randomized, multicenter trial involving 1395 HL patients (median age, 33; range, 16–75) who were diagnosed with early unfavorable HL. Unfavorable disease was defined as stage I or II …

About this research paper

What this paper is about

Combined modality chemotherapy plus involved field radiotherapy (IFRT) provides high cure rates in patients with stage I–II Hodgkin lymphoma (HL). However, each modality carries excess risks for acute and delayed toxicities and for relapse among patients with unfavorable clinical features. To compare outcomes associated with various chemotherapy regimens and IFRT doses, investigators in the German Hodgkin Study Group conducted a randomized, multicenter trial involving 1395 HL patients (median age, 33; range, 16–75) who were diagnosed with early unfavorable HL. Unfavorable disease was defined as stage I or II …

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Combined modality chemotherapy plus involved field radiotherapy (IFRT) provides high cure rates in patients with stage I–II Hodgkin lymphoma (HL). However, each modality carries excess risks for acute and delayed toxicities and for relapse among patients with unfavorable clinical features. To compare outcomes associated with various chemotherapy regimens and IFRT doses, investigators in the German Hodgkin Study Group conducted a randomized, multicenter trial involving 1395 HL patients (median age, 33; range, 16–75) who were diagnosed with early unfavorable HL. Unfavorable disease was defined as stage I or II …

Key concepts: Medicine, Hodgkin lymphoma, Stage (stratigraphy), Radiation therapy, Internal medicine, Lymphoma, Chemotherapy, Disease

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Combination Therapy for Early Unfavorable Hodgkin Lymphoma — Research Paper | ScholarLens